GeneCentric Therapeutics and Janssen Research & Development have formed a research alliance focused on RNA-based drug response biomarkers for non-muscle invasive bladder cancer (NMIBC).
GeneCentric Therapeutics has acquired Select ImmunoGenomics, a Chapel Hill, NC-based provider of advanced immunogenomic, data analysis and biomarker development services to support the development of immuno-oncology drugs.
GeneCentric Therapeutics, Inc. today announced that it has entered into a research collaboration with the University of North Carolina at Chapel Hill (UNC) to assess patient response to....